Haloperidol

Haloperidol is an effective dopamine D2 receptor antagonist that can be used to induce models of tardive dyskinesia and Parkinson’s disease.

Haloperidol hydrochloride, a potent dopamine D2 receptor antagonist, is an effective antipsychotic agent.

Haloperidol decanoate (KD 16) is a typical antipsychotic agent utilized as maintenance treatment for schizophrenia and mood disorders formulated as an ester for intramuscular injection.

Haloperidol lactate is a potent antipsychotic. haloperidol lactate has potential for studies in psychiatric disorders. haloperidol lactate can be used in acute and chronic schizophrenia and polyarousal syndrome.

Haloperidol-D4 trifluoroacetate is a deuterated compound of Haloperidol trifluoroacetic acid.

Reduced Haloperidol-D4 is a deuterated compound of Reduced Haloperidol. Reduced Haloperidol (T37167) has a CAS number of 34104-67-1.

Reduced Haloperidol (Standard) is a reference standard for research and analysis in studies involving Reduced Haloperidol. Reduced haloperidol is an active metabolite of haloperidol . It is formed via reduction of haloperidol by ketone reductase. Reduced haloperidol inhibits radioligand binding to sigma-1 and dopamine D2 receptors (Kis = 1.4 and 31 nM, respectively) and stimulates brain-derived neurotrophic factor (BDNF) secretion from CCF-SSTG1 and U87MG astrocytic glial cells. It also inhibits norepinephrine, dopamine, and serotonin (5-HT) reuptake (Kis = 21, 25, and 33 μM, respectively, in COS-7 cells expressing the human transporters). Reduced haloperidol (0.5 mg/kg) increases latency to paw withdrawal in mouse models of capsaicin- but not force-induced mechanical hypersensitivity.

Haloperidol-D4 is deuterium-labeled Haloperidol (TMSM-3424).

Reduced haloperidol is an active metabolite of haloperidol . It is formed via reduction of haloperidol by ketone reductase. Reduced haloperidol inhibits radioligand binding to sigma-1 and dopamine D2 receptors (Kis = 1.4 and 31 nM, respectively) and stimulates brain-derived neurotrophic factor (BDNF) secretion from CCF-SSTG1 and U87MG astrocytic glial cells. It also inhibits norepinephrine, dopamine, and serotonin (5-HT) reuptake (Kis = 21, 25, and 33 μM, respectively, in COS-7 cells expressing the human transporters). Reduced haloperidol (0.5 mg/kg) increases latency to paw withdrawal in mouse models of capsaicin- but not force-induced mechanical hypersensitivity.

Haloperidol (Standard) is a reference standard for research and analysis in studies involving Haloperidol. Haloperidol is an effective dopamine D2 receptor antagonist that can be used to induce models of tardive dyskinesia and Parkinson’s disease.

Haloperidol-13C6 (Standard) is a reference standard of Haloperidol-13C6 intended for quantitative analysis, quality control, and related biochemical research applications.

Haloperidol-[13C6] (Standard) is a reference standard of Haloperidol-[13C6] intended for quantitative analysis, quality control, and related biochemical research applications.

Reduced Haloperidol-[D4] (Standard) is a reference standard of Reduced Haloperidol-[D4] intended for quantitative analysis, quality control, and related biochemical research applications.

Haloperidol D4 (Standard) is a reference standard of Haloperidol D4 intended for quantitative analysis, quality control, and related biochemical research applications.

HPTP is a monoaminergic neurotoxin related to MPTP. It is the dehydration product of haloperidol. The agent is specifically a dopaminergic and serotonergic neurotoxin. HPTP is a prodrug of HPP+, which mediates its monoaminergic neurotoxicity, HPTP can be utilized for building neurotoxic or immuno-deficient model for research related to neuroscience.

Palmitoyl glutamic acid (N-Palmitoyl-L-glutamic acid) is an acyl amino acid that inhibits aortic constriction and counteracts haloperidol-induced oral motility disorders.

Spiperone (Spiropitan) is a spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.

Raseglurant (ADX-10059) is a negative allosteric modulator of the mGlu5 receptor that demonstrates efficacy against migraine and significantly reduces haloperidol-induced catalepsy in mice, Raseglurant is widely used in neuropharmacology research to study glutamatergic modulation, motor side effects of antipsychotics, and migraine-related signaling pathways.

Carpipramine (free base) is an atypical antipsychotic compound utilized in France and Japan to treat schizophrenia and anxiety. In addition to its neuroinhibitory and anxiolytic effects, it also possesses hypnotic properties. Structurally, carpipramine resembles tricyclic compounds like imipramine and is related to butyrophenones such as haloperidol.

Loperamide is a opioid-receptor selective agonist. Its chemical structure is similar to that of haloperidol and pethidine, and it is suitable for acute diarrhea as well as chronic diarrhea caused by various etiology.

A-86929 is a potent and selective dopamine D1 receptor agonist with a pKi of 7.3. It significantly induces rotational behavior in a 6-OHDA-induced unilateral nigral lesion rat model and improves motor function in an MPTP-induced Parkinson's disease marmoset model. Furthermore, A-86929 shows potential value in reducing cocaine-induced craving behavior in rats and reversing Haloperidol-induced cognitive deficits in rhesus monkeys. The compound is useful for researching neurological disorders.

VU0477886 is a potent mGlu4 positive allosteric modulator (PAM) with robust efficacy in a standard preclinical Parkinson's disease model, haloperidol-induced catalepsy (HIC).

Acetyl β-endorphin (1-26) is a neuropeptide found in rat hippocampus, brain stem, and pituitary. It is also present in the human hypothalamus, where it comprises approximately 4.9% of total β-endorphin peptides. Acetyl β-endorphin (1-26) is produced through posttranslational processing of β-endorphin and is processed similarly in rat and human hypothalamus. Levels of acetyl β-endorphin (1-26) increase in the rat pars intermedia and brain stem following chronic administration of haloperidol .

Antibacterial agent 67 significantly inhibited the activity of succinate dehydrogenase with an IC50 value of 0.03 μM and showed significantly higher enzymatic inhibitory activity against succinate dehydrogenase than haloperidol (IC50= 4.40 μM).